Overall rank by patents
#31,728
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
G21 S.r.l.
USPTO PatentsView assignee record - 8 granted patents across 7 technology areas, active 2018–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).
8
Total patents granted
7
CPC technology areas
9.4
Avg claims per patent
+600%
5-year filing velocity
The verdict
G21 holds 8 US patents across 7 technology areas, rank #31,728 of 50,000 tracked assignees.
- #31,728
- of 50,000 US assignees by volume
- Top 76%
- by Innovation Score (27.6/100)
- 9.4
- avg claims per patent
- +600%
- filing velocity, last 5 yrs
Portfolio overview
G21 S.r.l. has been granted 8 US utility patents between 2018 and 2024, placing G21 S.r.l. at rank #31,728 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 9.4 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a Foreign Corporation, G21 S.r.l. is one of the more focused assignees in the PatentsView dataset. By volume, G21 sits between Future Systems Besitz Gmbh (8 patents, rank #31,724) and GDC Technology (shenzhen) Limited (8 patents, rank #31,732) - the closest US assignees by grant volume. The composite Innovation Score of 27.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 7 grants, compared with 1 in the 2015–2019 window, a +600% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. G21 S.r.l.'s 9.4 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark G21 S.r.l. against peers pursuing similar technology classes.
Who files at G21's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Future Systems Be…
Future Systems Besitz GmbH
8 patents
- G A W
G.A.W. Inc
8 patents
- G Mondini S P A
G.MONDINI S.P.A.
8 patents
- G Skill Internati…
G.SKILL INTERNATIONAL ENTERPRISE CO., LTD.
8 patents
- GARY Sharp Innova…
GARY SHARP INNOVATNONS, LLC
8 patents
- Gastroklenz
GASTROKLENZ INC.
8 patents
- GBS Laboratories
GBS Laboratories, LLC
8 patents
- GDC Technology (S…
GDC Technology (Shenzhen) Limited
8 patents
- G21 S R L ◀
G21 S.R.L.
8 patents
What this shows G21 holds 8 patents at rank #31,728, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near G21
By rank, the assignees closest to #31,728 in granted patent volume.
- Future Systems Besitz Gmbh #31,724 · 8 patents
- G.a.w. Inc #31,725 · 8 patents
- G.mondini S.p.a. #31,726 · 8 patents
- G.skill International Enterprise Co., Ltd. #31,727 · 8 patents
- GARY Sharp Innovatnons, Llc #31,729 · 8 patents
- Gastroklenz Inc. #31,730 · 8 patents
- GBS Laboratories, Llc #31,731 · 8 patents
- GDC Technology (shenzhen) Limited #31,732 · 8 patents
Leaders in A61F (Filters Implantable INTO Blood Vessels)
Other assignees with the most granted patents in G21's primary technology class.
- The Procter & Gamble Company 1,426 in class
- Boston Scientific Scimed, Inc. 1,101 in class
- Edwards Lifesciences Corporation 1,101 in class
- Depuy Synthes Products, Inc. 851 in class
- Globus Medical, Inc. 752 in class
- COOK Medical Technologies Llc 700 in class
- Smith & Nephew, Inc. 541 in class
- Covidien Lp 528 in class
G21's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
28 Top 76% higher than 24% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 1 | 12.5% |
| 2020 | 3 | 37.5% |
| 2021 | 1 | 12.5% |
| 2022 | 1 | 12.5% |
| 2024 | 2 | 25.0% |
Which technologies does G21 S.r.l. patent most?
Top 7 of 7 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Simple
Velocity Accelerating
Frequently Asked Questions
How many patents does G21 S.r.l. hold?
G21 S.r.l. holds 8 US granted patents filed between 2018 and 2024, spanning 7 technology areas.
What is G21 S.r.l.'s Innovation Score?
G21 S.r.l. has an Innovation Score of 27.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does G21 S.r.l. focus on?
G21 S.r.l.'s top technology area is A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS) with 6 patents. The company has filed patents in 7 CPC subclasses total.
Is G21 S.r.l.'s patent filing rate increasing or decreasing?
G21 S.r.l.'s recent filing velocity is +600% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for G21 S.r.l.'s patents?
G21 S.r.l.'s patents average 9.4 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the G21 S.r.l. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
G21's 8 grants land it in the top 76% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - G21 ranks #31,728 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61F - see who else leads that technology area. A61F leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.